非血缘脐血移植联合DCAG方案在急性髓系白血病初次诱导治疗中的疗效观察  

Clinical Observation of Non-consanguineous Umbilical Cord Blood Transplantation Combined with DCAG Regimen in the Primary Induction Therapy of Acute Myeloid Leukemia

作　　者：徐斌 王迪 徐金环[1] 姜利军 李春蕊[1] 肖毅[1] XU Bin;WANG Di;XU Jin-huan;JIANG Li-jun;LI Chun-rui;XIAO Yi(Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院血液内科,湖北武汉430030

出　　处：《中国血液流变学杂志》2021年第1期19-22,共4页Chinese Journal of Hemorheology

基　　金：国家自然科学基金面上项目(82070213,81873444);湖北省科技厅重点研发计划(2020BCB021);湖北省卫健委面上项目(WJ2019M126)。

摘　　要：目的探讨非血缘脐血移植联合DCAG方案治疗急性髓系白血病(AML)中初次诱导治疗的疗效观察。方法回顾性分析接受非血缘脐血移植联合DCAG方案治疗14例AML患者的临床资料。中位年龄57(45~66)岁,FAB分型:M15例、M22例、M55例、MDS转化AML 2例。所有患者均采用地西他滨联合CAG方案诱导化疗。结果14例AML患者中有11例患者通过脐血移植联合化疗均获得完全缓解,1例获得部分缓解,2例未缓解。骨髓抑制期显著缩短。结论非血缘脐血移植联合DCAG化疗显著提高AML缓解率,缩短骨髓抑制期。Objective To investigate the efficacy of non-consanguine umbilical cord blood transplantation combined with DCAG in the treatment of acute myeloid leukemia(AML).Methods The clinical data of 14 patients with AML treated with non-consanguineous umbilical cord blood transplantation and DCAG regimen were retrospectively analyzed.The median age was 57(45-66)years old,and the classification of FAB was:5 cases of M1,2 cases of M2,5 cases of M5,and 2 cases of MDS transformed AML.All patients were treated with dicitabine combined CAG regimen to induce chemotherapy.Results Among the 14 AML patients,11 patients obtained complete remission through umbilical cord blood transplantation combined with chemotherapy,1 obtained partial remission and 2 did not.The myelosuppression period was significantly shortened.Conclusion Non-consanguine umbilical cord blood transplantation combined with DCAG chemotherapy can saignificantly improve the remission rate of AML and shorten the myelosuppression period.

关 键 词：非血缘脐血移植 急性髓系白血病 初次诱导 完全缓解率 

分 类 号：R733.71[医药卫生—肿瘤]